Generali Investments Management Co LLC Has $4.28 Million Stock Holdings in Stryker Corporation $SYK

Generali Investments Management Co LLC boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 7.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,822 shares of the medical technology company’s stock after purchasing an additional 736 shares during the quarter. Stryker comprises approximately 1.0% of Generali Investments Management Co LLC’s investment portfolio, making the stock its 26th biggest position. Generali Investments Management Co LLC’s holdings in Stryker were worth $4,276,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Consolidated Portfolio Review Corp grew its stake in Stryker by 4.2% in the 2nd quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after buying an additional 26 shares during the last quarter. Princeton Global Asset Management LLC boosted its holdings in shares of Stryker by 16.9% during the second quarter. Princeton Global Asset Management LLC now owns 180 shares of the medical technology company’s stock worth $71,000 after acquiring an additional 26 shares during the period. Sunflower Bank N.A. grew its position in shares of Stryker by 4.0% in the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock valued at $275,000 after purchasing an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC increased its stake in shares of Stryker by 3.2% during the second quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock worth $341,000 after purchasing an additional 27 shares during the period. Finally, Sachetta LLC lifted its holdings in Stryker by 58.7% during the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the completion of the transaction, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. This represents a 9.27% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at $4,886,921.71. This represents a 3.84% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 520,500 shares of company stock valued at $184,803,065. Insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Truist Financial upped their price objective on Stryker from $392.00 to $400.00 and gave the company a “hold” rating in a report on Friday. Barclays upped their price target on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. UBS Group set a $408.00 price objective on shares of Stryker in a research note on Monday, October 13th. Royal Bank Of Canada restated an “outperform” rating and set a $435.00 target price on shares of Stryker in a research report on Friday. Finally, Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Thirteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $434.37.

Stryker Stock Performance

Shares of NYSE:SYK opened at $362.39 on Friday. Stryker Corporation has a 1 year low of $329.16 and a 1 year high of $406.19. The stock has a market capitalization of $138.59 billion, a price-to-earnings ratio of 48.00, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The company’s 50 day simple moving average is $371.96 and its 200 day simple moving average is $381.22.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. During the same quarter last year, the business posted $2.87 EPS. The company’s revenue was up 10.2% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, research analysts predict that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.